IDEXX Laboratories, Inc. vs Redwire Corporation — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Redwire Corporation trades at $9.58 (market cap $2.44B). The key difference: IDEXX Laboratories, Inc. is far larger — about 16.6× Redwire Corporation's market cap, and Redwire Corporation is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Redwire Corporation for 18 Days on average.
| IDXX | RDW | |
|---|---|---|
Market Cap | $40.43B | $2.44B |
Volume | 692,164 | 11,053,212 |
Sector | Health | Industrials |
52-Week High | $766.68 | $25.90 |
52-Week Low | $504.70 | $5.06 |
Typical Hold Time | 46 Days | 18 Days |
Enterprise Value | $41.32B | $1.97B |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding the $3.94 estimate. Revenue grew to $4.3 billion in 2025, and net income margin expanded to 25.03%. Recent acquisitions like CoVetAI aim to enhance veterinary workflow intelligence.
The outlook remains positive given robust profitability and analyst consensus, but risks include foreign exchange headwinds and competitive pressures. With a consensus price target of $665, representing ~30% upside, the stock offers growth potential for investors comfortable with its premium valuation multiples.
RDW trades at $9.76, down 4.69% on the day, with a bearish technical signal and oversold RSI readings near 27. The company reported a net loss of $226.55 million for 2025, with negative margins, but revenue grew to $335.38 million and is projected to reach $426 million in 2026. Recent news highlights partnerships in space robotics and a $981 million Space Force contract award, signaling growth potential in defense and space infrastructure.
Despite consistent earnings misses and negative profitability, analyst consensus is strongly bullish with an 80% buy rating and a $14.88 price target, implying significant upside. Key risks include high cash burn, dependence on SpaceX's Starship success, and competitive pressures. The stock presents a high-risk, high-reward opportunity for investors betting on the expanding space economy.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →